SurVaxM is under clinical development by MimiVax and currently in Phase I for Central Nervous System (CNS) Tumor. According to GlobalData, Phase I drugs for Central Nervous System (CNS) Tumor have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SurVaxM’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SurVaxM overview

SurVaxM is under development for the treatment of glioblastoma, brain cancer, recurrent gioblastoma, high grade glioma, multiple myeloma, neuroendocrine tumors including neuroendocrine gastroenteropancreatic tumors and pediatric medulloblastoma, glioblastoma multiforme, anaplastic astrocytoma, high-grade astrocytoma, anaplastic oligodendroglioma, anaplastic ependymoma, ependymoma and diffuse intrinsic pontine gliomas. The vaccine candidate is administered through subcutaneously. SVN53-67/M57-KLH is a peptide vaccine containing a 15-mer peptide with C to M modification at the amino acid position 57. It is derived from the anti-apoptosis protein survivin. It is conjugated with keyhole limpet hemocyanin (KLH).

It was under development for the treatment of autoimmune diseases.

MimiVax overview

MimiVax operates as a pharmaceutical company that discovers and develops immunotherapeutic vaccines and targeted therapies for the treatment of cancer. The company’s lead candidate is SurVaxM. Its SurVaxM is a cancer vaccine that stimulates a potent immune response and the survivin molecule and an important cellular protein that sustains the viability of tumor cells and can be delivered through a simple injection. MimiVax’s SurVaxM is under clinical trials in recurrent glioma and newly diagnosed glioblastoma; prolongs survival in pre-clinical models of ovarian, brain, renal and prostate cancers. survivin is a cell-survival protein that is present in most cancer and rarely detectable in normal tissue and immunotherapeutic vaccine demonstrate safety and tolerability in a phase. MimiVax is headquartered in Buffalo, New York, the US.

For a complete picture of SurVaxM’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.